, Volume 16, Issue 3, pp 666–674 | Cite as

Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders

  • Sandeep Kumar SinghEmail author
  • Saurabh Srivastav
  • Rudolph J. Castellani
  • Germán Plascencia-Villa
  • George PerryEmail author


Alzheimer’s disease (AD) is the most common progressive human neurodegenerative disorder affecting elderly population worldwide. Hence, prevention of AD has been a priority of AD research worldwide. Based on understanding of disease mechanism, different therapeutic strategies involving synthetic and herbal approaches are being used against AD. Among the herbal extract, Ginkgo biloba extract (GBE) is one of the most investigated herbal remedy for cognitive disorders and Alzheimer’s disease (AD). Standardized extract of Ginkgo biloba is a popular dietary supplement taken by the elderly population to improve memory and age-related loss of cognitive function. Nevertheless, its efficacy in the prevention and treatment of dementia remains controversial. Specifically, the added effects of GBE in subjects already receiving “conventional” anti-dementia treatments have been to date very scarcely investigated. This review summarizes recent advancements in our understanding of the potential use of Ginkgo biloba extract in the prevention of AD including its antioxidant property. A better understanding of the mechanisms of action of GBE against AD will be important for designing therapeutic strategies, for basic understanding of the underlying neurodegenerative processes, and for a better understanding of the effectiveness and complexity of this herbal medicine.

Key Words

Alzheimer’s disease Antioxidant Dietary supplement Ginkgo biloba extract Herbal compounds Neurodegenerative disease 



This work was performed with resources from the following non-profit organizations: Indian Scientific Education and Technology Foundation (ISET Foundation), Lucknow, India, the Alzheimer’s Association, and the National Institute of Health (GIZ-MD007591), USA.

Required Author Forms

Disclosure forms provided by the authors are available with the online version of this article.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

13311_2019_767_MOESM1_ESM.pdf (1.1 mb)
ESM 1 (PDF 1152 kb)
13311_2019_767_MOESM2_ESM.pdf (1.4 mb)
ESM 2 (PDF 1456 kb)


  1. 1.
    Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer’s disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998;51 (1 Suppl 1):S2–17.Google Scholar
  2. 2.
    Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol 2011;10 (9):819–28.Google Scholar
  3. 3.
    Singh SK, Sinha P, Mishra L, et al. Neuroprotective role of a novel copper chelator against induced neurotoxicity. Int J Alzheimers Dis 2013; 2013.Google Scholar
  4. 4.
    Kumar A, Srivastava S, Tripathi S, Singh SK, Srikrishna S, Sharma A. Molecular insight into amyloid oligomer destabilizing mechanism of flavonoid derivative 2-(4′ benzyloxyphenyl)-3-hydroxy-chromen-4-one through docking and molecular dynamics simulations. J Biomol Struct Dyn 2016;34(6):1252–63.Google Scholar
  5. 5.
    Singh SK, Gaur R, Kumar A, Fatima R, Mishra L, Srikrishna S. The flavonoid derivative 2-(4′ benzyloxyphenyl)-3-hydroxy-chromen-4-one protects against Aβ42-induced neurodegeneration in transgenic drosophila: insights from in silico and in vivo studies. Neurotox Res 2014;26(4):331–50.Google Scholar
  6. 6.
    Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer’s disease. Brain 2006;129(11):2840–55.Google Scholar
  7. 7.
    Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012;75(3):311–35.Google Scholar
  8. 8.
    Asadi S, Ahmadiani A, Esmaeili MA, Sonboli A, Ansari N, Khodagholi F. In vitro antioxidant activities and an investigation of neuroprotection by six Salvia species from Iran: a comparative study. Food Chem Toxicol 2010;48(5):1341–9.Google Scholar
  9. 9.
    Singh SK, Srivastav S, Yadav AK, et al. Overview of Alzheimer’s disease and some therapeutic approaches targeting Aβ by using several synthetic and herbal compounds. Oxidative Med Cell Longev 2016; 2016.Google Scholar
  10. 10.
    Dumont M, Beal MF. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol Med 2011;51(5):1014–26.Google Scholar
  11. 11.
    Kubitzki K. In: Kramer K, Greech PS, editors. The families and genera of vascular plants— pteridophytes and gymnosperms. Berlin: Springer Verlag; 1990. p. 284.Google Scholar
  12. 12.
    Hori T, Ridge RW, Tulecke W, Del Tredici P, Trémouillaux-Guiller J, Tobe H, editors. Ginkgo biloba a global treasure: from biology to medicine Springer Science & Business Media; 2012.Google Scholar
  13. 13.
    Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012;11(10):851–9.Google Scholar
  14. 14.
    Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998;55(11):1409–15.Google Scholar
  15. 15.
    Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996;29:47–56.Google Scholar
  16. 16.
    Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997;278:1327–1332.Google Scholar
  17. 17.
    Napryeyenko O, Borzenko I. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung 2007;57:4–11.Google Scholar
  18. 18.
    Yancheva S, Ihl R, Nikolova G, et al. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer’s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health 2009;13:183–190.Google Scholar
  19. 19.
    Mix JA, Crews WD, Jr. A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol 2002;17:267–277.Google Scholar
  20. 20.
    DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH. Ginkgo biloba for prevention of dementia: a randomized controlled trial. Jama 2008;300(19):2253–62.Google Scholar
  21. 21.
    McCarney R, Fisher P, Iliffe S, van Haselen R, Griffin M, van der Meulen J, Warner J. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry 2008;23(12):1222–30.Google Scholar
  22. 22.
    Schindowski K, Leutner S, Kressmann S, Eckert A, Muller WE. Age-related increase of oxidative stress-induced apoptosis in mice prevention by Ginkgo biloba extract (EGb761). J Neural Transm 2001;108:969–978.Google Scholar
  23. 23.
    Smith JV, Burdick AJ, Golik P, et al. Anti-apoptotic properties of Ginkgo biloba extract EGb 761 in differentiated PC12 cells. Cell MolBiol (Noisy-le-grand) 2002;48:699–707.Google Scholar
  24. 24.
    Leuner K, Hauptmann S, Abdel-Kader R, et al. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer’s disease? Antioxid Redox Signal 2007;9:1659–1675.Google Scholar
  25. 25.
    Abdel-Kader R, Hauptmann S, Keil U, et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res 2007;56:493–502.Google Scholar
  26. 26.
    Luo Y, Smith JV, Paramasivam V, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci U S A 2002;99:12197–12202.Google Scholar
  27. 27.
    Eckert A, Keil U, Scherping I, Hauptmann S, Muller WE. Stabilization of Mitochondrial Membrane Potential and Improvement of Neuronal Energy Metabolism by Ginkgo Biloba Extract EGb 761. Ann N Y Acad Sci 2005;1056:474–485.Google Scholar
  28. 28.
    Eckert A, Keil U, Kressmann S, et al. Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsychiatry 2003;36(Suppl 1)S15–23.Google Scholar
  29. 29.
    Kwant, Cor. Hiroshima: A Bombed Ginkgo. The Ginkgo Pages Internet Explorer April 18, 2006.
  30. 30.
    Wanadoo. Internet Explorer April 18, 2006.
  31. 31.
    Griggs B. GREEN PHARMACY: The History and Evolution of Western Herbal Medicine. New York: Viking Press, 1981) p. 326.Google Scholar
  32. 32.
    Le Bars PL. Magnitude of effect and special approach to Ginkgo biloba extract EGb761 in cognitive disorders. Pharmacopsychiatry 2003;36:S44–S49.Google Scholar
  33. 33.
    Smith PF, Maclennan K, Darlington CL. The neuroprotective properties of the Ginkgo biloba leaf a review of the possible relationship to platelet-activating factor (PAF). J Ethnopharmacol 1996;50:131–139.Google Scholar
  34. 34.
    Shi C, Zhao L, Zhu B, Li Q, Yew DT, Yao Z, Xu J. Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against beta-amyloid peptideinduced toxicity in SH-SY5Y cells. Chem Biol Interact 2009;181:115–123.Google Scholar
  35. 35.
    Maclennan KM, Darlington CL, Smith PF. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol 2002;67:235–257.Google Scholar
  36. 36.
    Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci 2003;60:1779–1792.Google Scholar
  37. 37.
    Christen Y. Ginkgo biloba and neurodegenerative disorders. Front Biosci. 2004;9:3091 3104.Google Scholar
  38. 38.
    Smith JV, Luo Y. Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol 2004;64:465–472.Google Scholar
  39. 39.
    Luo Y. Ginkgo biloba neuroprotection: Therapeutic implications in Alzheimer’s disease. J Alzheimers Dis 2001;3:401–407.Google Scholar
  40. 40.
    Saleem S, Zhuang H, Biswal S, Christen Y, Doré S. Ginkgo biloba extract neuroprotectiveaction is dependent on heme oxygenase 1 in ischemic reperfusion brain injury. Stroke 2008;39:3389–3396.Google Scholar
  41. 41.
    Ponto LL, Schultz SK. Ginkgo biloba extract: Review of CNS effects. Ann Clin Psychiatry 2003;15:109–119.Google Scholar
  42. 42.
    Luo Y. Alzheimer’s disease, the nematode Caenorhabditis elegans, and ginkgo biloba leaf extract. Life Sci 2006;78:2066–2072.Google Scholar
  43. 43.
    Holstein N. Ginkgo special extract EGb 761 in tinnitus therapy. An overview of results of completed clinical trials. Fortschr Med Orig 2001;118:157–164.Google Scholar
  44. 44.
    Schneider B. Ginkgo biloba extract in peripheral arterial diseases: Meta-analysis of controlled clinical studies. Arzneimittelforschung 1992;42:428–436.Google Scholar
  45. 45.
    Wheatley D. Ginkgo biloba in the treatment of sexual dysfunction due to antidepressant drugs. Hum Psychopharmacol 1999;14:512–513.Google Scholar
  46. 46.
    Diamond BJ, Shiflett SC, Feiwel N, et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 2000;81:668–678Google Scholar
  47. 47.
    Yue TL, Feuerstein GZ. Platelet-activating factor: a putative neuromodulator and mediator in the pathophysiology of brain injury. Crit Rev Neurobiol 1994;8:11–24.Google Scholar
  48. 48.
    Gohil K, Moy RK, Farzin S, Maguire JJ, Packer L. mRNA expression profile of a human cancer cell line in response to Ginkgo biloba extract: induction of antioxidant response and the Golgi system. Free Radic Res 2000;33:831–49.Google Scholar
  49. 49.
    Dower JI, Geleijnse JM, Gijsbers L, Schalkwijk C, Kromhout D, Hollman PC. Supplementation of the pure flavonoids epicatechin and quercetin affects some biomarkers of endothelial dysfunction and inflammation in (Pre)hypertensive adults: a randomized double-blind, placebo-controlled, crossover trial. J Nutr 2015;145:1459–63.Google Scholar
  50. 50.
    Dower JI, Geleijnse JM, Gijsbers L, Zock PL, Kromhout D, Hollman PC. Effects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health: a randomized, double-blind, placebo-controlled, crossover trial. Am J Clin Nutr 2015;101:914–21.Google Scholar
  51. 51.
    Yin Y, Ren Y, Wu W, et al. Protective effects of bilobalide on Aβ(25–35) induced learning and memory impairments in male rats. Pharmacol Biochem Behav 2013;106:77–84.Google Scholar
  52. 52.
    Jiang M, Li J, Peng Q , et al. Neuroprotective effects of bilobalide on cerebral ischemia and reperfusion injury are associated with inhibition of pro-inflammatory mediator production and down-regulation of JNK1/2 and p38 MAPK activation. J Neuroinflammation 2014;11:167.Google Scholar
  53. 53.
    Mahmoud F, Abul H, Onadeko B, Khadadah M, Haines D, Morgan G. In vitro effects of Ginkgolide B on lymphocyte activation in atopic asthma: comparison with cyclosporin A. Jpn J Pharmacol 2000;83(3):241–5.Google Scholar
  54. 54.
    Nakanishi K. Terpene trilactones from Gingko biloba: from ancient times to the 21st century. Bioorg Med Chem 2005;13(17):4987–5000.Google Scholar
  55. 55.
    Bairy KL. Wound healing potentials of plant products. J Nat Rem 2002;2(1):11–20.Google Scholar
  56. 56.
    Louajri A, Harraga S, Godot V, Toubin G, Kantelip JP, Magnin P. The effect of ginkgo biloba extract on free radical production in hypoxic rats. Biol Pharm Bull 2001;24(6):710–2.Google Scholar
  57. 57.
    Zeng K, Li M, Hu J, et al. Ginkgo biloba extract EGb761 attenuates Hyperhomocysteinemia-induced AD like tau hyperphosphorylation and cognitive impairment in rats. Curr Alzheimer Res 2018;15(1):89–99Google Scholar
  58. 58.
    Yuan Q, Wang CW, Shi J, Lin ZX. Effects of Ginkgo biloba on dementia: An overview of systematic reviews. J Ethnopharmacol 2017;195:1–9Google Scholar
  59. 59.
    Srivastav S, Fatima M, Mondal AC. Important medicinal herbs in Parkinson’s disease pharmacotherapy. Biomed Pharmacother 2017;92:856-63.Google Scholar
  60. 60.
    Smith TC, Ryan MA, Smith B, et al. Complementary and alternative medicine use among US Navy and Marine Corps personnel. BMC Complement Altern Med 2007;7:16.Google Scholar
  61. 61.
    DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets 2000;1:25–58.Google Scholar
  62. 62.
    Werneke U, Turner T, Priebe S. Complementary medicines in psychiatry: review of effectiveness and safety. Br J Psychiatry 2006;188:109–21.Google Scholar
  63. 63.
    Hechtman L. Attention –deficit / Hyperactivity disorder. In: Sadock BJ, Sadock VA, eds. Comprehensive Text Book of Psychiatry. 8th ed. Philadelphia: Lippincott Williams & Wilkins;2005.Google Scholar
  64. 64.
    Noorbala AA, Akhondzadeh S. AttentionDeficit/Hyperactivity Disorder: Etiology and Pharmacotherapy. Arch Iran Med 2006;9:374–80.Google Scholar
  65. 65.
    Himi T, Saito H, Nishiyama N. Effect of ginseng saponins on survival of cerebral cortex neurons in cell cultures. Chem Pharm Bull (Tokyo) 1989;37:481–4.Google Scholar
  66. 66.
    Garg RK, Nag D, Agrawal A. A double blind placebo controlled trial of ginkgo biloba extract in acute cerebral ischaemia. J Assoc Physicians India 1995;43:760–3.Google Scholar
  67. 67.
    White HL, Scates PW, Cooper BR. Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci 1996;58:1315–21.Google Scholar
  68. 68.
    Kumar Singh S, Barreto E G, Aliev G, Echeverria V. Ginkgo biloba as an alternative medicine in the treatment of anxiety in dementia and other psychiatric disorders. Curr Drug Metab 2017;18(2):112–9.Google Scholar
  69. 69.
    Ahlemeyer B, Krieglstein J. Neuroprotective effects of the Ginkgo biloba extract. In: Phytomedicine of Europe: Chemistry and Biological activity, ACS Symposium Series. 1998.Google Scholar
  70. 70.
    Ni Y, Zhao B, Hou J, Xin W. Preventive effect of Ginkgo biloba extract on apoptosis in rat cerebellar neuronal cells induced by hydroxyl radicals. Neurosci Lett 1996;214(2–3):115–8.Google Scholar
  71. 71.
    Oyama Y, Chikahisa L, Ueha T, Kanemaru K, Noda K. Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide. Brain Res 1996;712(2):349–52.Google Scholar
  72. 72.
    Chen C, Wei T, Gao Z, et al. Different effects of the constituents of EGb761 on apoptosis in rat cerebellar granule cells induced by hydroxyl radicals. IUBMB Life 1999;47(3):397–405.Google Scholar
  73. 73.
    Song W, Guan HJ, Zhu XZ, Chen ZL, Yin ML, Cheng XF. Protective effect of bilobalide against nitric oxide-induced neurotoxicity in PC12 cells. Acta Pharmacol Sin 2000;21(5):415–20.Google Scholar
  74. 74.
    Xin W, Wei T, Chen C, Ni Y, Zhao B, Hou J. Mechanisms of apoptosis in rat cerebellar granule cells induced by hydroxyl radicals and the effects of EGb761 and its constituents. Toxicology 2000;148(2–3):103–10.Google Scholar
  75. 75.
    Zhou LJ, Zhu XZ. Reactive oxygen species-induced apoptosis in PC12 cells and protective effect of bilobalide. J Pharmacol Exp Ther 2000;293(3):982–8.Google Scholar
  76. 76.
    Guidetti C, Paracchini S, Lucchini S, Cambieri M, Marzatico F. Prevention of neuronal cell damage induced by oxidative stress in-vitro: effect of different Ginkgo biloba extracts. J Pharm Pharmacol 2001;53(3):387–92.Google Scholar
  77. 77.
    Klein J, Chatterjee SS, Löffelholz K. Phospholipid breakdown and choline release under hypoxic conditions: inhibition by bilobalide, a constituent of Ginkgo biloba. Brain Res 1997;755(2):347–50.Google Scholar
  78. 78.
    Krieglstein J, Ausmeier F, El-Abhar H, et al. Neuroprotective effects of Ginkgo biloba constituents. Eur J Pharm Sci 1995;3(1):39–48.Google Scholar
  79. 79.
    Zhu L, Gao J, Wang Y, Zhao XN, Zhang ZX. Neuron degeneration induced by verapamil and attenuated by EGb761. J Basic Clin Physiol Pharmacol 1997;8(4):301–14.Google Scholar
  80. 80.
    Bastianetto S, Ramassamy C, Doré S, Christen Y, Poirier J, Quirion R. The ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by β-amyloid. Eur J Neurosci 2000;12(6):1882–90.Google Scholar
  81. 81.
    Zhou LJ, Song W, Zhu XZ, Chen ZL, Yin ML, Cheng XF. Protective effects of bilobalide on amyloid beta-peptide 25-35-induced PC12 cell cytotoxicity. Acta Pharmacol Sin 2000;21(1):75–9.Google Scholar
  82. 82.
    Yang SF, Wu Q, Sun AS, Huang XN, Shi JS. Protective effect and mechanism of Ginkgo biloba leaf extracts for Parkinson disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Acta Pharmacol Sin 2001;22(12):1089–93.Google Scholar
  83. 83.
    Bastianetto S, Zheng WH, Quirion R. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C. J Neurochem 2000;74(6):2268–77.Google Scholar
  84. 84.
    Zhang WR, Hayashi T, Kitagawa H, et al. Protective effect of ginkgo extract on rat brain with transient middle cerebral artery occlusion. Neurol Res 2000;22(5):517–32.Google Scholar
  85. 85.
    Rabin O, Drieu K, Grange E, Chang MC, Rapoport SI, Purdon AD. Effects ofEGb 761 on fatty acid reincorporation during reperfusion following ischemia in the brain of the awake gerbil. Mol Chem Neuropathol 1998;34(1):79–101.Google Scholar
  86. 86.
    Calapai G, Crupi A, Firenzuoli F, et al. Neuroprotective effects of Ginkgo biloba extract in brain ischemia are mediated by inhibition of nitric oxide synthesis. Life Sci 2000;67(22):2673–83.Google Scholar
  87. 87.
    Chandrasekaran K, Mehrabian Z, Spinnewyn B, Drieu K, Fiskum G. Neuroprotective effects of bilobalide, a component of the Ginkgo biloba extract (EGb 761), in gerbil global brain ischemia. Brain Res 2001;922(2):282–92.Google Scholar
  88. 88.
    Oberpichler H, Beck T, Abdel-Rahman MM, Bielenberg GW, Krieglstein J. Effects of Ginkgo biloba constituents related to protection against brain damage caused by hypoxia. Pharmacol Res Commun 1988;20(5):349–68.Google Scholar
  89. 89.
    Sharma HS, Drieu K, Alm P, Westman J. Role of nitric oxide in blood-brain barrier permeability, brain edema and cell damage following hyperthermic brain injury. In: An experimental study using EGB-761 and Gingkolide B pretreatment in the rat. InBrain Edema XI 2000 (pp. 81-86). Vienna: Springer.Google Scholar
  90. 90.
    Bolaños-Jiménez F, de Castro RM, Sarhan H, Prudhomme N, Drieu K, Fillion G. Stress-induced 5-HT1A receptor desensitization: protective effects of Ginkgo biloba extract (EGb 761). Fundam Clin Pharmacol 1995;9(2):169–74.Google Scholar
  91. 91.
    Trovero F, Brochet D, Tassin JP, Drieu K. Ginkgo biloba extract EGb761 reduces the development of amphetamine-induced behavioral sensitization: effects on hippocampal type II corticosteroid receptors. Brain Res 1999;818(1):135–9.Google Scholar
  92. 92.
    Ferrante RJ, Klein AM, Dedeoglu A, Beal MF. Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis. J Mol Neurosci 2001;17(1):89–96.Google Scholar
  93. 93.
    Gohil, K.; Packer, L. Global gene expression analysis identifies cell and tissue specific actions ofGinkgo biloba extract, EGb 761. Cell Mol Biol 2002, 48, 625–631.Google Scholar
  94. 94.
    Gerlai, R. Alzheimer’s disease: Beta-amyloid hypothesis strengthened! Trends Neurosci 2001, 24,199.Google Scholar
  95. 95.
    Shi C, Zhao L, Zhu B, et al. Protective effects of Ginkgo bilobaextract (EGb761) and its constituents quercetin and ginkgolide B against beta-amyloid peptideinduced toxicity in SH-SY5Y cells. Chem Biol Interact 2009;181:115–123.Google Scholar
  96. 96.
    Bastianetto S, Ramassamy C, Doré S, Christen S, Poirier J, Quirion R. The Ginkgo bilobaextract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 2000, 12, 1882–1890.Google Scholar
  97. 97.
    Smith JV, Luo Y. Elevation of oxidative free radicals in Alzheimer’s disease models can be attenuated by Ginkgo biloba extract EGb 761. J Alzheimers Dis 2003, 5, 287–300.Google Scholar
  98. 98.
    Yao ZX, Han Z, Drieu K, Papadopoulos V. Ginkgo biloba extract (EGb 761) inhibits betaamyloid production by lowering free cholesterol levels. J Nutr Biochem 2004, 15, 749–756.Google Scholar
  99. 99.
    Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: A review of their intracellular targets. Eur J Pharmacol 2006, 545, 51–64.Google Scholar
  100. 100.
    Bodovitz, S.; Klein, W.L. Cholesterol modulates alpha-secretase cleavage of amyloid precursorprotein. J Biol Chem 1996, 271, 4436–4440.Google Scholar
  101. 101.
    Howland DS, Trusko SP, Savage MJ, et al. Modulation of secreted beta-amyloidprecursor protein and amyloid beta-peptide in brain by cholesterol. J Biol Chem 1998;273:16576–16582.Google Scholar
  102. 102.
    Simons M, Keller P, de Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998;95:6460–6464.Google Scholar
  103. 103.
    Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 1991;563:311–314.Google Scholar
  104. 104.
    Simmons LK, May PC, Tomaselli KJ, et al. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol 1994;45:373–379.Google Scholar
  105. 105.
    Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer’s therapy. Nat Med 1998;4:822–826.Google Scholar
  106. 106.
    Tsuzuki K, Yamaguchi H, Tateno M, Imai K, Fujii N, Yamauchi T. Transthyretin binds amyloid beta peptides, A beta 1-42 and A beta 1-40 to form complex in the autopsied human kidney possible role of transthyretin for abeta sequestration. Neurosci Lett 2000;281:171–174.Google Scholar
  107. 107.
    Watanabe CM, Wolffram S, Ader P, et al. The in vivo neuromodulatory effects of the herbal medicine Ginkgo biloba. Proc Natl Acad Sci U S A 2001;98:6577–6580.Google Scholar
  108. 108.
    Kaur N, Dhiman M, Perez-Polo JR, Mantha AK. Ginkgolide B revamps neuroprotective role of apurinic/apyrimidinic endonuclease 1 and mitochondrial oxidative phosphorylation against Aβ25–35-induced neurotoxicity in human neuroblastoma cells. J Neurosci Res 2015;93(6):938–47.Google Scholar
  109. 109.
    Rhein V, Giese M, Baysang G, et al. Ginkgo biloba extract ameliorates oxidative phosphorylation performance and rescues Aβ-induced failure. PLoS One 2010;5(8):e12359.Google Scholar
  110. 110.
    Gella A, Durany N. Oxidative stress in Alzheimer disease. Cell Adhes Migr 2009;3:88–93.Google Scholar
  111. 111.
    Pohanka M. Alzheimer s disease and oxidative stress: a review. Curr Med Chem 2014;21(3):356–64.Google Scholar
  112. 112.
    Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443(7113):787.Google Scholar
  113. 113.
    Perry G, Cash AD, Smith MA. Alzheimer disease and oxidative stress. Biomed Res Int 2002;2(3):120–3.Google Scholar
  114. 114.
    Wei T, Ni Y, Hou J, Chen C, Zhao B, Xin W. Hydrogen peroxide-induced oxidative damage and apoptosis in cerebellar granule cells: Protection by Ginkgo biloba extract. Pharmacol Res 2000;41:427–433.Google Scholar
  115. 115.
    Wu Y, Wu Z, Butko P, et al. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 2006;26:13102–13113.Google Scholar
  116. 116.
    Bridi R, Crosetti FP, Steffen VM, Henriques AT. The antioxidant activity of standardized extract of Gingko biloba (EGb 761) in rats. Phytother Res 2001;15:449–451.Google Scholar
  117. 117.
    Colak Ö, Sahin A, Alatas Ö, Inal M, Yasar B, Kiper H. The effect of Ginkgo biloba on the activity of catalase and lipid peroxidation in experimental strangulation ileus. Int J Clin Lab Res 1998;28:69–71.Google Scholar
  118. 118.
    Sasaki K, Hatta S, Wada K, et al. Effects of extract of Ginkgo biloba leaves and its constituents on carcinogen metabolizing enzyme activities and glutathione levels in mouse liver. Life Sci 2002;70:1657–1667.Google Scholar
  119. 119.
    Rimbach G, Gohil K, Matsugo S, et al. Induction of glutathione synthesis in human keratinocytes by Ginkgo biloba extract (EGb 761). Biofactors 2001;15:39–52Google Scholar
  120. 120.
    Maitra I, Marcocci L, Droy-Lefaix MT, Packer L. Peroxyl radical scavenging activity of Ginkgo biloba extract EGb 761. Biochem Pharmacol 1995;45:1649–1655.Google Scholar
  121. 121.
    Gohil K, Packer L. Global gene expression analysis identifies cell and tissue specific actions of Ginkgo biloba extract, EGb 761. Cell Mol Biol 2002;48:625–631.Google Scholar
  122. 122.
    Sestili P, Guidarelli A, Dacha M, Cantoni O. Quercetin prevents DNA single strand breakage and cytotoxicity caused by tert-butylhydroperoxide: Free radical scavenging versus iron chelating mechanism. Free Radic Biol Med 1998;25:196–200.Google Scholar
  123. 123.
    Scholtyssek H, Damerau W, Wessel R, Schimke I. Antioxidative activity of ginkgolides against superoxide in an aprotic environment. Chem Biol Interact 1997;106:183–190.Google Scholar
  124. 124.
    Pietri S, Maurelli E, Drieu K, Culcasi M. Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol 1997;29:733–742.Google Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2019

Authors and Affiliations

  1. 1.Indian Scientific Education and Technology FoundationLucknowIndia
  2. 2.School of Life SciencesJawaharlal Nehru UniversityNew DelhiIndia
  3. 3.School of MedicineWest Virginia UniversityMorgantownUSA
  4. 4.College of SciencesThe University of Texas at San AntonioSan AntonioUSA

Personalised recommendations